Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
25.60
-0.41 (-1.58%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Company Description
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Jon Congleton |
Contact Details
Address: 150 N. Radnor Chester Road, Suite F200 Radnor, Pennsylvania 19087 United States | |
| Phone | 888 378 6240 |
| Website | mineralystx.com |
Stock Details
| Ticker Symbol | MLYS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1933414 |
| CUSIP Number | 603170101 |
| ISIN Number | US6031701013 |
| Employer ID | 84-1966887 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jon Congleton | President, Chief Executive Officer and Director |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder and Executive Director |
| Adam Scott Levy | Chief Financial Officer and Secretary |
| Jose Breton CPA | Senior Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 21, 2026 | 144 | Filing |
| Aug 17, 2026 | 144 | Filing |
| Aug 13, 2026 | 144 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 10, 2026 | 144 | Filing |
| Aug 6, 2026 | SCHEDULE 13G/A | Filing |
| Jul 21, 2026 | 144 | Filing |
| Jul 17, 2026 | 144 | Filing |
| Jul 15, 2026 | 144 | Filing |